To further elucidate the regulatory dynamics of CLEC-2 in the context of breast cancer progression, future mechanistic studies should incorporate tumor tissue immunohistochemistry along with simultaneous quantification of plasma podoplanin levels. This evidence concerns the gene PDPN and breast cancer.